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ABSTRACT 
Background: Cholangiocarcinoma (CC), is the second most common primary liver cancer in 
most parts of the world. In western countries, primary sclerosing cholangitis (PSC) is one of 
the most common causes of CC. CC has a low survival rate, between 2-30% depending on 
type and spread, and diagnosis often comes late in the development of the tumor, due to a late 
clinical presentation and unsatisfactory diagnostic methods. It is particularly difficult to 
determine if biliary strictures in patients with PSC are benign or malignant in nature. In recent 
years, there has been an increased interest in the use of proteomic analysis of bile for the 
discovery of potential biomarkers to aid in the diagnosis of CC. 
 
Objective: The aim was to determine the existence of proteins whose relative abundance in 
bile differs depending on the underlying disease, in patients with biliary strictures. The main 
ambition was to discover one or more proteins with the ability to distinguish a benign biliary 
stricture from a malignant stricture in patients with PSC. 
 
Methods: Bile samples from 37 patients were analyzed in this prospective exploratory study, 
including 5 patients with de novo CC, 4 with CC and PSC, 7 with PSC only, 6 with pancreatic 
cancer, and 15 controls. The bile was aspirated from patients undergoing endoscopic 
retrograde cholangiopancreatography. For one sample, bile was aspirated by percutaneous 
transhepatic cholangiography. Nano liquid chromatography tandem mass spectrometry was 
used for mass analysis. Proteins were identified by searches against a public database of 
human peptide sequences. Lastly, SPSS Statistical Package was used to calculate if there was 
a statistically significant difference in abundance of proteins between patient groups. 
 
Results: A total of 6 proteins were identified where the relative abundance differed 
significantly between patient groups (p < 0.05). The most promising finding was that the 
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known tumor suppressor Receptor-type tyrosine-protein phosphatase eta (R-PTP-eta) was less 
abundant in patients with CC than in the control population and patients with PSC only. 
 
Conclusions: The differential abundance of certain proteins present in human bile, such as R-
PTP-eta, can be used to differentiate CC from other diseases of the bile ducts. None of the 
proteins described in this study were alone able to distinguish a benign biliary stricture from a 
malignant stricture in patients with PSC. Further studies are warranted to examine the 
usefulness of these proteins as clinical tumor markers for CC. 
 
The abbreviations used in this report are: CC, Cholangiocarcinoma; PSC, Primary sclerosing cholangitis; 
MRCP, Magnetic resonance cholangiopancreatography; ERCP, Endoscopic retrograde 
cholangiopancreatography; CT, Computed tomography; CA 19-9, Serum carbohydrate antigen 19-9; CEA, 
Carcinoembryonic antigen; LC-MS/MS, Liquid Chromatography Tandem Mass Spectrometry; GuHCl, 
Guanidine HCl; R-PTP-eta, Receptor-type tyrosine-protein phosphatase eta. 
 
INTRODUCTION 
Cholangiocarcinoma. Bile duct cancer, or cholangiocarcinoma (CC) is a malignant tumor 
that originates in the epithelial cells that line the bile ducts. While CC is a relatively rare form 
of cancer, it is the second most prevalent primary liver cancer after hepatocellular carcinoma 
in most parts of the world[1]. Since CC rarely occurs before the age of 40[2], the incidence is 
consequently higher in older populations than in the Swedish population as a whole; the 
majority of Swedish patients diagnosed with CC in 2013 were 70 years of age or older[3]. In 
2013, the incidence of CC per 100,000 Swedish inhabitants in the age group 40 years and 
older was 4.74[3,4]. The risk of developing CC is slightly higher for men than for women[1]. 
Over the past decades there has been a worldwide increase in the incidence and mortality of 
CC, according to epidemiological studies[1,5]. While the etiology of most cases of CC is 
unknown[2], there are still several known risk factors for developing the disease, all of which 
have chronic biliary inflammation in common[1]. In Western countries, primary sclerosing 
cholangitis (PSC) is one of the most common causes of CC[1].  
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CC can be classified according to its location as being either intra-hepatic or extra-hepatic, 
with the latter being the most common manifestation of the tumor[1]. The extra-hepatic tumors 
can in turn be divided into distal and hilar lesions. Hilar lesions are tumors with an origin at 
the confluence of the right and left hepatic ducts; these are often referred to as Klatskin 
tumors[6]. The distal lesions occur along the common bile duct[7] (Fig. 1). 
 
 
Figure 1. Anatomy of the bile ducts. The location of different forms of CC are marked in shades of gray 
(Gustafsson A, 2015). 
 
The course of the disease, its clinical presentation, incidence, and risk factors differ somewhat 
depending on which of these subtypes the CC belongs to[1,2]. What all forms of CC have in 
common is that they are notoriously difficult to diagnose early on in their development, with a 
late and often unspecific clinical presentation, and a high mortality rate. Statistics from the 
U.S. National Cancer Institute show that the 5-year relative survival for patients diagnosed 
with either intra-hepatic or extra-hepatic CC in the years 2000 to 2006 was between 2-15% 
and 2-30% respectively, depending on how far the cancer had spread from its point of 
origin[8]. 
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Primary Sclerosing Cholangitis. As mentioned previously PSC is one of the most common 
causes of CC[1]. It is a chronic disorder characterized by inflammation and fibrosis of both the 
intra-hepatic and extra-hepatic bile ducts. Over time strictures may develop, which are 
abnormally narrowed ductal segments. There is a strong association with inflammatory bowel 
disease: approximately 70% of patients with PSC also have ulcerative colitis[9]. This 
association with ulcerative colitis, together with observations of lymphocytic infiltrates in the 
tissue surrounding the affected ducts, and circulating auto-antibodies in the plasma of PSC 
patients, suggests that PSC may be an immunologically mediated disease. How these findings 
relate to the pathogenesis of PSC still remains to be clarified[9,10]. 
 
While no more than 10% of CC can be attributed to PSC[2], the relative risk of developing CC 
is significantly increased in PSC patients compared with the general population. In a Swedish 
study with a cohort of 604 PSC patients, the frequency of CC was observed to be 13%[11]. 
Patients who develop CC as a result of underlying PSC are generally younger than patients 
who develop it de novo. The median age of patients diagnosed with PSC has been calculated 
as 41 years, and in those who also develop CC, the malignancy is frequently detected within 
the first 1-3 years after diagnosis of PSC[10]. 
 
The symptoms of PSC are cholestatic; the obstruction of bile flow from the liver to the 
duodenum causes systemic retention of bilirubin and other solutes which are normally 
eliminated in bile. In the case of PSC, this obstruction is due to stricturing of the bile ducts. 
The symptoms include jaundice, pruritus, dark urine and pale stools[9]. Other common 
symptoms are abdominal pain, fever, and fatigue. Magnetic resonance 
cholangiopancreatography (MRCP) is the preferred method for identifying PSC, having 
supplanted endoscopic retrograde cholangiopancreatography (ERCP) in this respect. 
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Nonetheless, ERCP is still used for investigations of symptomatic PSC patients where biliary 
obstruction or CC is suspected[10]. 
 
A feared complication of PSC is the formation of dominant strictures. These are defined as a 
stenosis ≤ 1.5 mm in the common bile duct or ≤ 1 mm in the hepatic duct. With current 
diagnostic methods, it is difficult to differentiate between benign and malignant dominant 
strictures[10]. Given the mortality rates of CC, this is crucial to determine in order to ensure a 
prompt and adequate treatment. The need for novel and accurate diagnostic methods for this 
purpose is great. 
 
Diagnosing Cholangiocarcinoma. There are several factors that complicate the process of 
diagnosing CC. The first factor can be attributed to the insidious progress of the disease. Most 
patients are diagnosed with CC when the cancer is already at an advanced stage and often 
unresectable, having a survival of less than 12 months following diagnosis[7]. 
 
The second complicating factor lies with the symptoms themselves. Since they are so 
unspecific, there are many differential diagnoses to consider. Extra-hepatic CC is a cholestatic 
disease, and patients present with painless jaundice, dark urine, pale stools, pruritus, malaise, 
and weight loss[1,7]. Patients with intra-hepatic CC present with abdominal pain, malaise, 
weight loss, and decreased appetite. Sometimes an incidentally found abdominal mass is the 
only finding[1]. When a patient presents with these symptoms, the presence of CC or 
pancreatic malignancy must be suspected and evaluated, but many other diagnoses must also 
be considered and ruled out, e.g. gallbladder cancer, PSC, benign biliary strictures, and 
gallstones[7]. 
 
The third factor that complicates the diagnosing of CC is the lack of accurate diagnostic 
methods. There is currently no test that alone can diagnose bile duct malignancies with 
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confidence. Many different modalities are combined in clinical practice to achieve the best 
possible diagnostic accuracy: imaging techniques, endoscopy, cytology, and serum tumor 
markers[10]. Even so, in some difficult cases the results of these combined efforts are 
inconclusive. 
 
Computed tomography (CT) is very sensitive for detecting intra-hepatic CC larger than 1 
cm[1]. However, today CT has mostly been replaced with magnetic resonance imaging and 
MRCP for diagnosing and staging CC. This technique can reveal both the site and extent of 
tumor involvement as well as vascular involvement[1]. The sensitivity of MRCP for 
differentiating between benign and malignant biliary strictures ranges from 30-98%[12]. 
 
ERCP is one of the main tools in diagnosing CC. With this endoscopic technique, the bile 
ducts can be visualized in detail, and stenosing tumors along the bile ducts can be easily 
detected[1]. For the purpose of determining the etiology of a biliary stricture, ERCP has a 
diagnostic accuracy comparable to that of MRCP[12]. The downside is that ERCP, unlike 
MRCP and CT, is an invasive procedure; there is always the risk of complications such as 
bacterial cholangitis and pancreatitis. In a systematic survey of prospective studies of post-
ERCP complications, Andriulli et al. reported a morbidity of 6.85% and a mortality of 0.33% 
that could be attributed to complications of the procedure[13]. 
 
During ERCP, brush cytology can be used to obtain cell samples for analysis. The diagnostic 
yield of this method is very low, from 9-24%[1]. Complicating matters further, it is difficult to 
evaluate cell samples from patients with PSC, due to the inflammatory, reactive changes often 
found in these patients[14]. Fluorescence in situ hybridization and digital image analysis is a 
more sensitive method, which is often combined with brush cytology to increase the 
diagnostic accuracy[1]. 
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Tumor markers such as serum carbohydrate antigen 19-9 (CA 19-9), carcinoembryonic 
antigen (CEA), and cancer antigen 125 can be elevated in patients with CC[1,15]. Some studies 
have evaluated the possibility of using these and other existing tumor markers to diagnose 
CC, based on their presence in serum and bile, but they are not specific enough to be used 
clinically as tumor markers for CC[1,16]. 
 
Bile Proteomics. Bile proteomics is the scientific field devoted to identifying and quantifying 
the proteins that can be found in bile, more specifically human bile. The field has existed for 
decades, but has recently become more popular by building on the field of cancer proteomics: 
proteomic analysis of body fluids targeted at "the discovery of new clinically useful 
biomarkers" to detect cancer[17]. The principle behind cancer proteomics is that changes in the 
abundance of certain proteins occur during the development of malignant cells, which can be 
detected in the biological fluids in close contact with the malignant tissue[15,17], e.g. bile 
containing proteins secreted from a malignant biliary stricture. In the recent decade several 
proteomic studies have been conducted, aimed at discovering potential biomarkers for CC. 
 
Liquid chromatography and tandem mass spectrometry (LC-MS/MS) is often used in 
proteomics for protein identification. It is an analytical technique that couples a liquid 
chromatograph to a tandem mass spectrometer to first separate the substances in a sample and 
then identify and quantify them. In the case of a sample containing peptides, the sequence of 
amino acids can be determined for each peptide, which can thus be identified. The process 
starts with liquid chromatography, where the peptides are eluted through a solid column by a 
liquid mobile phase. Peptides with a lower affinity to the column are eluted first, and by 
changing the chemical composition of the mobile phase, peptides with greater affinity to the 
column can be displaced and are eluted last. In this way the peptides in the sample can be 
separated based on their chemical properties. In tandem mass spectrometry two mass 
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analyzers are arranged in sequence. The peptides are first ionized and fragmented, 
subsequently the mass and charge of each fragment is analyzed, and in this way the peptide 
sequence is determined. The relative abundance of each ion is plotted in a mass spectrum as a 
function of the mass-to-charge ratio of the ion, represented graphically as peaks (Fig. 9). It is 
then possible to identify the components of a sample by the mass spectrum, in this example 
peptides in a sample of bile[18]. 
 
Objective. In this study the aim was to determine the existence of proteins whose relative 
abundance in bile differs depending on the underlying disease, in patients with biliary 
strictures. Such proteins could have potential as clinical tumor markers to diagnose CC at an 
earlier stage. It would be desirable to establish a tumor marker that has both a high sensitivity 
and a high specificity for differentiating between benign and malignant biliary strictures, 
particularly in patients with PSC. 
 
METHODS 
The scope of this master's thesis covers part of a larger ongoing study of the bile proteome 
which is being conducted at the Department of Medical Biochemistry, Institute of 
Biomedicine, University of Gothenburg, and at the Gastroenterologic Endoscopic ward at 
Sahlgrenska University Hospital, Gothenburg, Sweden. The study was approved by the 
Regional Ethical Review Board in Gothenburg, and written informed consent was obtained 
from all patients included in the study. 
 
Collection of Bile 
Bile samples were collected from patients undergoing ERCP at the Gastroenterologic 
Endoscopic ward, Sahlgrenska University Hospital. Additionally, plasma, urine and saliva 
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was also collected from some of the patients, for future analysis and evaluation of less 
invasive methods for detecting potential tumor markers. Indications for undergoing ERCP 
were: clinical symptoms related to bile duct disorder (e.g. jaundice), extraction of gallstones, 
investigation of a biliary stricture or suspected tumor, and the insertion or removal of stents in 
the bile ducts. 
 
ERCP was performed with a common duodenoscope and according to clinical practice. 
Before the injection of contrast medium 1-3 ml of bile was aspirated by a catheter positioned 
in the extrahepatic bile duct. One of the patients included in this study had acquired a 
percutaneous transhepatic biliary drainage, and in that case bile was passively emptied 
through the drain. The bile sample was flushed into a plastic tube and put on ice, and within 1 
h transported to a -80°C freezer for storage. Samples were thawed immediately before 
preparation of the bile for proteomic analysis. 
 
Selection of Samples 
The patient groups included in this study were: de novo CC, CC with concurrent PSC, PSC, 
pancreatic cancer, and lastly, patients with benign biliary diseases such as gallstones, 
pancreatitis, cholangitis, or benign strictures of the bile ducts. This latter category of patients 
with benign diseases served as controls in this study. In order to categorize the patients into 
the aforementioned groups, relevant clinical information was obtained through reading of 
their patient histories. 
 
For this master's thesis, bile samples from 37 of the patients included in the larger study were 
selected for proteomic analysis. The subset of selected patients had been included in the study 
between January 2014 and January 2015. We included 5 patients with de novo CC (median 
age 62, range 57-80, 80% males), 4 patients with CC and concurrent PSC (median age 45, 
Gustafsson A. 11 
range 33-70, 75% males), 7 patients with PSC only (median age 35, range 20-65, 71% males), 
6 patients with pancreatic cancer (median age 67, range 52-75, 83% males), and 15 controls 
(median age 70, range 32-84, 60% males). 36 of the samples selected for analysis in this study 
were collected by ERCP, 1 sample was collected by percutaneous transhepatic biliary 
drainage. All bile samples that were analyzed had been collected distal to the biliary stricture 
(closer to the duodenum than the liver), in the cases where such a stricture was found. The 
only exclusion criterion was current malignancy other than CC and pancreatic cancer. One 
CC patient also had prostate cancer, but his disease was not spread and we reasoned that it 
would likely not affect the protein content of the bile, so he was included despite this. For a 
summary of the demographic and medical data of these patients, see Table 1 below. 
 
Table 1. 
Demographic and medical data for the 37 patients analyzed in this study. 
Diagnosis Indication for ERCP Age at 
ERCP 
(years) 
Gender 
(M/F) 
Other conditions 
CC Bile obtained through 
percutaneous transhepatic biliary 
drainage. 
57 M - 
CC (Klatskin tumor) Investigation of stricture. 80 M Renal failure. 
CC (distal tumor) Jaundice. 61 M Prostate cancer. 
CC (Klatskin tumor) Cholestasis, abdominal pain. 62 F Liver metastasis. 
CC (Klatskin tumor) Investigation of stricture. 70 M - 
CC and PSC (Klatskin 
tumor) 
Investigation of stricture. 33 M Ulcerative colitis. 
Colectomized. 
CC and PSC (Klatskin 
tumor) 
Jaundice, pruritus. 40 M Ulcerative colitis. 
Colectomized. 
CC and PSC (Klatskin 
tumor) 
Investigation of stricture. 70 F Ulcerative colitis. Prior 
thyroid cancer. 
CC and PSC (intra-hepatic 
tumor) 
Investigation of stricture. 50 M Ulcerative colitis. 
PSC Investigation of stricture. 42 M Ulcerative colitis. 
Cirrhosis. Colectomized. 
PSC Removal of stent. 29 F - 
PSC Investigation of stricture. 36 M - 
PSC Stenting of stricture. 65 M Ulcerative colitis. 
PSC Concrements on ultrasound. 26 M Ulcerative colitis. 
PSC Investigation of strictures. 20 M Ulcerative colitis. 
PSC Dilatation of stricture. 35 F Ulcerative colitis. 
Pancreatic cancer Pancreatic cancer on CT. 75 M Diabetes. Hypertension. 
Pancreatic cancer Jaundice. 52 M - 
Pancreatic cancer Investigation of stricture. 64 M - 
Pancreatic cancer Investigation of stricture. 60 M Pancreatitis. 
Pancreatic cancer Change of stent. 70 F Cholecystectomized. 
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Table 1 (continued). 
Demographic and medical data for the 37 patients analyzed in this study. 
Diagnosis Indication for ERCP Age at 
ERCP 
(years) 
Gender 
(M/F) 
Other conditions 
Gallstones Jaundice. 65 M Cholecystitis. 
Gallstones Concrements on MRCP. 57 F - 
Gallstones Removal of stent. 32 M - 
Gallstones Suspected gallstone. 74 M Cholangitis. Chronic 
obstructive pulmonary 
disease. 
Gallstones Cholestasis. 57 M Prior liver resection. 
Gallstones Control after stone extraction. 78 M Hypertension. 
Nephrectomized. 
Gallstones Concrements on ultrasound. 39 F - 
Gallstones Jaundice, abdominal pain. 83 M Angina pectoris. 
Hypertension. 
Benign stricture (distal) Abdominal pain, jaundice. 84 M Myocardial infarction. 
Benign stricture (hilar) Stenting of stricture. 74 F Cholangitis. 
Benign stricture Cholestasis, abdominal pain, 
weight loss. 
71 F Cholecystitis. 
Benign stricture (distal) Concrements on ultrasound. 70 F Pancreatitis. 
Cholecystitis Cholestasis. 70 F - 
Pancreatitis Suspected gallstone. 52 M Metabolic syndrome. 
No current hepatobiliary 
disorder 
Investigation of suspected 
stricture. 
70 M Ulcerative colitis. Liver 
transplanted for prior PSC. 
 
Bile Sample Preparation  
Filter Aided Sample Preparation. To prepare the bile for Nano LC-MS/MS analysis, a 
modified version of the Filter Aided Sample Preparation protocol, first described by 
Wisniewski et al. in 2009, was used[19]. First a portion (60 µl) of thawed bile was delipidated 
by addition of Cleanascite (Biotech Support Group, LLC., Monmouth Junction, NJ). The 
delipidated bile sample was then diluted in H2O at a ratio of 1:1. We continued with 12 µl of 
this dilution for each sample. Proteins were reduced through incubation with a buffer 
containing 6 M guanidine HCl (GuHCl), 0.1 M Tris HCl (pH 8.0), 5 mM 
ethylenediaminetetraacetic acid (EDTA), and 0.1 M dithiothreitol for 20 h at 37°C. Following 
centrifugation, the supernatant was loaded onto a ultrafiltration device with a molecular 
weight cut-off of 30 kDa and centrifuged at 7,000 g until the sample had passed through the 
filter. After washing with 200 µl of 6 M GuHCl, proteins were alkylated on-filter by addition 
of 50 µl of a solution containing 0.1 M Tris (pH 8,5) and 0.05 M iodoacetamide. Buffer 
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exchange was achieved by adding 100 µl of 50 mM ammonium bicarbonate (pH 8) and 
centrifuging the filter; this step was repeated once. 
 
Double Digestion with Lys-C and trypsin. The sample was sequentially digested using the 
two proteases Lys-C and trypsin. Each sample was ultimately divided into two fractions: one 
containing peptides digested with Lys-C, and the other containing peptides digested with Lys-
C and trypsin. Lys-C (Wako Pure Chemical Industries, Ltd.) was loaded onto the filter, which 
was left to incubate for 4 h at 37°C. The Lys-C digest was eluted by centrifugation at 10,000 
g, followed by addition of 0.5 M NaCl and centrifugation for 20 min at 10,000 g. The eluted 
Lys-C fraction was stored at 4°C overnight, while the filter was moved to a new collecting 
tube, to which trypsin (Promega, Madison, WI) and 50 mM ammoniumbicarbonate was 
added. This trypsin fraction was digested overnight at 37°C, and eluted as described above. 
 
Desalting and Concentration of Peptides. The Lys-C and trypsin fractions were acidifed and 
desalted on separate C18 StageTips, using a modified version of the protocol described in 
2003 by Rappsilber et al[20]. Each fraction was eluted and subsequently dried under vacuum. 
The vacuum dried peptides were redissolved in 0.2% formic acid, in order to protonate the 
peptides for analysis under positive ionization conditions in the mass spectrometer. The 
redissolved sample was centrifuged to sediment any larger particles that may have been eluted 
together with the sample. The top 15 µl of the sample were pipetted into a vial for mass 
spectrometry and stored at -20°C until analysis. 
 
Soon after Nano LC-MS/MS analysis was started, there were issues with high protein 
concentrations in the samples, which interfered with the mass analysis. This was solved by 
diluting all of the samples in 0.2% formic acid by a factor of 10 before continuing with the 
analysis. 
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Analysis 
Nano LC-MS/MS Analysis. Nano LC-MS/MS was used to identify the peptide sequences in 
the bile samples. Chromatographic separation of peptides was performed on an EASY-nLC 
1000 (Thermo Fisher Scientific) with a silica column. The peptides were eluted over 108 min 
using a stepwise gradient (Table 2), starting with 98% mobile phase A (0.2% formic acid in 
99.8% water) and 2% mobile phase B (0.2% formic acid in 80% acetonitrile and 19.8% 
water). The flow rate was constant at 200.00 nl/min. Mass spectrometrical analysis was 
performed on a Q Exactive instrument (Thermo Fisher Scientific), under positive ionization 
conditions. 
 
Table 2. 
The gradient used for Nano LC-MS/MS analysis. 
Time (min) Duration (min) Mobile phase B (%) 
0 5 2 
5 30 5 
35 20 15 
55 15 25 
70 30 60 
100 8 100 
 
Data Analysis. Raw data from the Nano LC-MS/MS analysis was compared against the 
human proteome using MaxQuant, version 1.4.1.2. The software was set up to search the 
Uniprot database UP000005640 (68,485 sequences, downloaded May 11, 2015). Fixed 
modifications were carbamidomethyl on cysteine residues (from alkylation), variable 
modifications were acetyl (protein N-term) and oxidation of methionine. Mass tolerance was 
4.5 ppm, signifying the maximum mass by which a peptide can differ from its theoretical 
mass in the database and still be identified as a match. In order to achieve a false discovery 
rate of < 1% a search against a decoy database was performed. The peptide intensities 
(equivalent to peptide abundance) were normalized with Intensity-based absolute 
quantification, where the raw peptide intensities are divided by the number of theoretically 
observable peptides from digestion with trypsin[21]. 
Gustafsson A. 15 
 
The data was exported to a Microsoft Excel file. Microsoft Excel was used to perform t-tests 
for each protein, comparing the average normalized peptide intensity between patient groups. 
Using the results of the t-tests, a list was compiled with the 50 proteins that showed the 
greatest difference in relative abundance; 43 of these proteins showed significant differences 
in abundance (p < 0.05) and 7 proteins did not show significant differences in abundance, but 
were included anyway because of the clinical importance of the diseases the proteins could 
differentiate between (CC and PSC vs. PSC, and de novo CC vs. CC and PSC) (Table 5 in the 
Appendix). Due to time limitations, only 8 of the most interesting proteins were chosen for 
further data analysis. The decision to include a protein for further analysis was based on: the 
p-value calculated by the t-test, the amount of different t-tests the protein showed differential 
abundance in, how great the difference in average peptide abundance was between patient 
groups, and the clinical importance of the diseases the protein could differentiate between. 
 
The final data analysis was performed with SPSS Statistical Package (IBM, SPSS Statistics 
for Windows, version 22.0). To calculate whether the difference in peptide intensity between 
patient groups was statistically significant or not at a significance level of 5%, non-parametric 
analyses were performed for these proteins (Mann-Whitney U-test and Kruskal-Wallis test). 
Box-plots for each protein of interest were obtained, depicting the differential peptide 
abundance (Fig. 2-7). Perseus, version 1.4.1.3, was used for principal component analysis of 
all proteins identified with MaxQuant, to test if any of them clustered according to diagnosis. 
This analysis translates correlated proteins into so-called components, to provide an objective 
assessment of how much the samples resemble each other. 
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RESULTS 
A total of 910 proteins were identified in the bile with Nano LC-MS/MS analysis. The 
amount of protein identifications varied greatly within patient groups (see Table 4 in the 
Appendix). t-tests performed on these proteins showed 43 proteins whose relative abundance 
differed significantly between patient groups. Table 5 in the Appendix compiles the 50 
proteins that showed the greatest difference in relative abundance after t-tests, including 7 
proteins that did not show significant differences in abundance, but might nevertheless be 
interesting to study. 
 
t-tests showed no significant difference in protein abundance between the patient groups of 
PSC only and "CC and PSC". However, since t-tests indicated that the protein Osteopontin 
was more abundant in PSC only than in the "CC and PSC" group (p = 0.054), this protein was 
deemed to be of interest for non-parametric testing in any case. t-tests did not show any 
significant difference in protein abundance between the patient groups of de novo CC and 
"CC and PSC" either, but Mucin-5B and Mucin-1 were both more abundant in de novo CC 
than in the "CC and PSC" group and in the control population (p = 0.052 and 0.11, 
respectively). The average peptide abundance of Mucin-1 was also slightly higher in de novo 
CC than in pancreatic cancer; the same was not observed for Mucin-5B. For these reasons, 
Mucin-1 was also deemed to be of interest for non-parametric testing. 
 
Out of the 8 proteins chosen for analysis using SPSS Statistical Package, non-parametric tests 
showed that the relative peptide abundance differed significantly between patient groups for 6 
proteins. These were: Receptor-type tyrosine-protein phosphatase eta (R-PTP-eta), Mucin-1, 
Cathelicidin antimicrobial peptide, Cytosolic non-specific dipeptidase, Ceruloplasmin, and 
Vitamin D-binding protein. The 2 proteins chosen for analysis that did not differ significantly 
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in peptide abundance between patient groups were Osteopontin and UPF0556 protein 
C19orf10. 
 
R-PTP-eta was present in 2 patients with de novo CC, 2 patients with CC and PSC, 2 patients 
with pancreatic cancer, 3 patients with PSC only, and in 8 controls. It was less abundant in 
patients with CC (including those with concurrent PSC) than in the control population (p = 
0.017) (Fig. 2A) and patients with PSC only (p = 0.034) (Fig. 2B). The median abundance of 
the protein was 4 times less for CC patients than for controls, and 13.5 times less for CC 
patients than for PSC patients. 
 
  
Figure 2. R-PTP-eta was less abundant in patients with CC (including those with concurrent PSC) than in the 
control population (A) and patients with PSC only (B). 
 
Mucin-1 was found in 3 patients with de novo CC, 3 patients with CC and PSC, 4 patients 
with pancreatic cancer, 4 patients with PSC only, and in 8 controls. It was more abundant in 
patients with de novo CC than in patients with CC and concurrent PSC, p = 0.050 (this figure 
was rounded up by SPSS, so we regarded the finding as significant) (Fig. 3). The median 
abundance of the protein was 10 times greater for patients with de novo CC than for patients 
with CC and PSC. 
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Figure 3. Mucin-1 was more abundant in patients with de novo CC than in patients with CC and concurrent PSC. 
The p-value 0.050 was rounded up by SPSS, so we regarded this finding as significant. 
 
 
Cathelicidin antimicrobial peptide was present in 3 patients with de novo CC, 3 patients with 
CC and PSC, 3 patients with pancreatic cancer, 5 patients with PSC only, and in 9 controls. It 
was more abundant in patients with PSC only than in patients with CC (including those with 
concurrent PSC) (p = 0.045) (Fig. 4A) and the control population (p = 0.039) (Fig. 4B). The 
median abundance of the protein was 35.5 times greater for PSC patients than for CC patients, 
and 22.5 times greater for PSC patients than for controls. 
 
  
Figure 4. Cathelicidin antimicrobial peptide was more abundant in patients with PSC only than in patients with 
CC (including those with concurrent PSC) (A) and the control population (B). 
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Figure 5. Cytosolic non-specific dipeptidase was more abundant in patients with de novo CC than in the control 
population. 
 
 
Cytosolic non-specific dipeptidase was present in 2 patients with de novo CC, 3 patients with 
CC and PSC, 5 patients with PSC only, and in 6 controls. It was more abundant in patients 
with de novo CC than in the control population (p = 0.046) (Fig. 5). The median abundance of 
the protein was 3.6 times greater for patients with de novo CC than for controls. 
 
  
Figure 6. Ceruloplasmin was more abundant in patients with CC (including those with concurrent PSC) than in 
the control population (A) and patients with pancreatic cancer (B). 
 
Ceruloplasmin was present in all 37 samples. It was more abundant in patients with CC 
(including those with concurrent PSC) than in the control population (p = 0.030) (Fig. 6A) 
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and patients with pancreatic cancer (p = 0.045) (Fig. 6B). The median abundance of the 
protein was 8.9 times greater for CC patients than for controls, and 10 times greater for CC 
patients than for patients with pancreatic cancer. It was also more abundant in patients with 
PSC (including those with concurrent CC) than in the control population (p = 0.046). 
 
Vitamin D-binding protein was present in all 37 samples. It was more abundant in patients 
with CC (including those with concurrent PSC) than in the control population (p = 0.030) 
(Fig. 7A). It was also more abundant in patients with PSC (including those with concurrent 
CC) than in the control population (p = 0.027) (Fig. 7B). The median abundance of the 
protein was 1.9 times greater for CC patients than for controls, and 6.9 times greater for PSC 
patients than for controls. 
 
  
Figure 7. Vitamin D-binding protein was more abundant in patients with CC (including those with concurrent 
PSC) than in the control population (A). It was also more abundant in patients with PSC (including those with 
concurrent CC) than in the control population. 
 
The results of principal component analysis did not show clustering according to diagnosis for 
any of the identified components. 
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Table 3. 
Potential biliary biomarker candidates. 
Protein Differentiates p-value 
R-PTP-eta CC from controls;  
CC from PSC. 
0.017; 
0.034 
Mucin-1 de novo CC from CC with concurrent PSC. 0.050 
Cathelicidin antimicrobial peptide PSC from controls; 
PSC from CC. 
0.039; 
0.045 
Cytosolic non-specific dipeptidase de novo CC from controls. 0.046 
Ceruloplasmin CC from controls; 
CC from pancreatic cancer; 
PSC (incl. concurrent CC) from controls. 
0.030; 
0.045; 
0.046 
Vitamin D-binding protein CC from controls; 
PSC (incl. concurrent CC) from controls. 
0.030; 
0.027 
 
 
DISCUSSION 
Nano LC-MS/MS followed by comparative proteomic analysis of bile samples from a cohort 
of 37 patients with either malignant biliary strictures, benign biliary strictures, or no biliary 
strictures, revealed several proteins with the potential to differentiate CC from other diseases 
of the bile ducts (Table 3). Unfortunately, none of the proteins described in this study were 
alone able to distinguish a benign biliary stricture from a malignant stricture in patients with 
PSC.  
 
R-PTP-eta. Since the main aim of this study was to examine whether it was possible to use 
biliary proteins to differentiate benign from malignant biliary strictures, the most interesting 
finding was perhaps R-PTP-eta, which was less abundant in patients with CC than in the 
control population and patients with PSC only (Fig. 2AB). The protein is a member of the 
protein tyrosine phosphatase family of signaling molecules that regulate cell growth, 
differentiation, mitotic cycle, and oncogenic transformation[22]. It is encoded in humans by the 
gene PTPRJ, which is known to be a tumor suppressor for various cancer types. Ruivenkamp 
et al. have demonstrated that loss of heterozygosity of PTPRJ is an early event in the 
development of colorectal cancer. One copy of the gene is also deleted in a large percentage 
of human lung and breast carcinomas[23]. Furthermore, PTPRJ is involved in the development 
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of papillary thyroid carcinoma, where both loss of heterozygosity and a generally decreased 
expression of PTPRJ protein have been shown in thyroid tumors[24]. It seems plausible then 
that decreased expression of PTPRJ protein likewise plays a role in the development of bile 
duct malignancies. R-PTP-eta was not able to differentiate between benign and malignant 
biliary strictures in PSC patients, either due to the limitations of the present study, or because 
its abundance really does not differ much between PSC patients with or without CC. Further 
studies more targeted at R-PTP-eta and with larger populations are warranted to examine this. 
In any case, R-PTP-eta could possibly be useful to help determine the etiology of biliary 
strictures in patients where a diagnosis of PSC has been ruled out. 
 
Mucin-1. Mucin-1 was less abundant in patients with CC and concurrent PSC than in patients 
with de novo CC (Fig. 3). It is a membrane-bound protein of the mucin family, encoded in 
humans by the MUC1 gene. Mucin-1 is involved in cell-adhesion and cell signaling[25]. 
Overexpression has been linked with several epithelial cancers, including pancreatic ductal 
adenocarcinoma and CC[26,27]. Tréhoux et al. recently showed that inhibiting the expression of 
Mucin-1 in vitro in pancreatic cancer cells decreases their proliferative, migratory, and 
invasive properties[26]. In the current study, Mucin-1 was only able to differentiate de novo 
CC from CC with concurrent PSC, and in clinical practice the diagnosis of PSC usually 
predates a diagnosis of CC, so its usefulness as a clinical biomarker is unclear. All the same, 
the differential abundance of Mucin-1 hints at a different pathogenesis for CC depending on 
whether it developed de novo or in a patient with PSC. 
 
Cathelicidin antimicrobial peptide. Cathelicidin antimicrobial peptide was more abundant in 
patients with PSC only than in the control population and patients with CC (Fig. 4AB). The 
protein is encoded by the gene CAMP, and belongs to a family of antimicrobial peptides. 
Besides antibacterial activities, it has antifungal and antiviral activities, and functions in cell 
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chemotaxis, immune mediator induction, and inflammatory response regulation[28]. 
Cathelicidin antimicrobial peptide is expressed in the human biliary epithelium and is 
secreted into the bile ducts in response to bacterial infection. Additionaly, bile salts induce 
cathelicidin antimicrobial peptide expression in the human biliary epithelium[29]. Cathelicidin 
antimicrobial peptide was unable to differentiate between benign and malignant biliary 
strictures in PSC patients. High amounts of the protein in bile appears to be specific for PSC, 
independent of an underlying malignancy. Considering its high abundance in bile from PSC 
patients, as well as the fact that it is secreted into the bile ducts in response to bacterial 
infection, this could suggest that the presence of bacteria in the bile ducts plays a role in the 
pathogenesis of PSC. 
 
Other Proteins of Interest. Cytosolic non-specific dipeptidase was more abundant in patients 
with de novo CC than in the control population (Fig 5). It is encoded in humans by the 
CNDP2 gene. It has been associated with a number of different cancer types. For example, the 
expression of Cytosolic non-specific dipeptidase in colon tumors has been shown to be 
significantly higher than in normal colon mucosa[30], whereas loss of the CNDP2 gene has 
been associated with adverse prognosis in patients with resected pancreatic cancer, as shown 
by Lee et al[31]. Interestingly, in this study the protein was not present in any of the 6 bile 
samples from patients with pancreatic cancer. 
 
Ceruloplasmin was more abundant in patients with CC than in the control population and 
patients with pancreatic cancer (Fig. 6AB). It was also more abundant in patients with PSC 
(including those with concurrent CC) than in the control population. It is a metalloprotein that 
binds copper in plasma, and is also involved in oxidation-reduction, cellular iron homeostasis, 
and transmembrane transport. The protein is encoded in humans by the gene CP[32]. Plasma 
levels of Ceruloplasmin are reduced in the majority of patients with Wilson disease, a disease 
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characterized by accumulation of copper in the liver. The affected gene in Wilson disease has 
been identified as ATP7B, and in a study of ATP7B knockout mice, copper accumulation led 
to changes in bile duct morphology consistent with CC[33]. It is unclear if this somehow 
relates to the finding of increased biliary Ceruloplasmin in CC patients in the current study. 
Ceruloplasmin could not differentiate between CC and PSC in this study. Like R-PTP-eta, 
Ceruloplasmin might however be useful for determining the etiology of biliary strictures in 
patients where a diagnosis of PSC has been ruled out. 
 
Vitamin D-binding protein was more abundant in patients with CC (including those with 
concurrent PSC) than in the control population (Fig. 7A). It was also more abundant in 
patients with PSC (including those with concurrent CC) than in the control population (Fig. 
7B). The protein is encoded in humans by the GC gene and belongs to the albumin gene 
family. It is found in many body fluids and on the surface of many cell types. The protein 
binds to vitamin D and its plasma metabolites and transports them to target tissues[34]. It is 
also related to inflammatory response regulation, as it enhances macrophage chemotaxis and 
activation. Different phenotypes of Vitamin D-binding protein appear to have different effects 
on the risk of developing cancer. In a Norwegian longitudinal study, Jorde et al. have found 
an association between the 1f/1f phenotype of Vitamin D-binding protein and a reduced risk 
of cancer, which they speculate could depend on its effect on macrophage activation. Another 
phenotype of the protein is associated with an elevated risk of gastrointestinal cancer[35]. In 
short, there appears to be an association between cancer and Vitamin D-binding protein, but 
not much has been reported on this subject. Both CC and PSC are diseases with a pronounced 
inflammatory aspect, so it is not surprising that the abundance of Vitamin D-binding protein 
is increased in these patient groups, considering its role in inflammatory response regulation. 
Since the protein is elevated in both of these diseases, it would probably not be a very good 
biomarker for diagnosing biliary strictures. 
Gustafsson A. 25 
 
Previous Studies of the Bile Proteome and Cholangiocarcinoma. Most proteomic studies of 
human bile have used sodium dodecylsulfate polyacrylamide gel electrophoresis and liquid 
chromatography mass spectrometry[36], and have analyzed bile samples from only a small 
number of patients. The results of one of the earliest mass spectrometric studies of the human 
bile proteome were reported in 2004 by Kristiansen et al. By fractioning bile from a CC 
patient with gel electrophoresis and analysing it with LC-MS/MS they were able to identify 
87 unique proteins[15]. In 2011, Lankisch et al. described a model for distinguishing CC from 
PSC, using capillary electrophoresis mass spectrometry to identify disease-specific peptide 
patterns, with a reported specificity of 78% and a sensitivity of 84%[36]. However, many of 
the proteins included in their biomarker model, such as hemoglobin, albumin, actin, and 
keratin, are found in high abundance in bile and are unspecific, or are likely contaminants. In 
2014, Farina et al. reported that they had analyzed 41 bile samples with high-performance 
LC-MS/MS, followed by immunoblot assessment of proteins overexpressed in their cancer 
samples. They found that Carcinoembryonic cell adhesion molecule 6 best detected cancer, 
and proposed a combined panel of biliary Carcinoembryonic cell adhesion molecule 6 and 
serum CA 19-9 to diagnose malignant biliary stenoses[37]. Farina et al. did not attempt to 
distinguish between different types of cancer with their biomarker, so the specificity of their 
proposed biomarker for detecting CC was not reported. Also in 2014, Navaneethan et al. 
reported that protein biomarkers in bile may differentiate malignant from benign biliary 
strictures. They had used liquid chromatography with mass spectrometry to identify the 
differential abundance of biliary proteins in bile samples from 24 patients. One of the proteins 
they identified as more abundant in CC samples than in PSC samples was Ceruloplasmin 
precursor[38], somewhat contrary to the findings of the current study, where Ceruloplasmin 
was most abundant in patients with PSC. 
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Other studies have tried to further the understanding of the pathogenesis of CC by analyzing 
the genetic profile of bile duct tumors. Osteopontin is a secreted glycoprotein with an 
important role in malignant cell attachment and tumor invasion. The gene encoding 
Osteopontin was identified in 2008 by Hass et al. to be the most overexpressed gene in CC. 
Surgical specimens from 10 patients, all containing histopathologically verified 
cholangiocellular carcinoma, were analyzed by oligonucleotide arrays[39]. In the current study, 
high levels of Osteopontin were found in bile from patients with de novo CC and patients 
with pancreatic cancer, but the differential abundance was not statistically significant between 
any patient groups. 
 
Some studies have aimed to develop novel biliary tumor markers for CC without the use of 
proteomic analysis. Matsuda et al. demonstrated in 2010 that an assay of sialylated Mucin-1 
in bile samples could diagnose CC with higher sensitivity than routine biliary cytology, but 
with a reported specificity of only 76.3%[27]. This corroborates the results of the current study, 
which strengthen the association of Mucin-1 to CC. Although Mucin-1 was not able to 
differentiate CC from controls, it could differentiate de novo CC from PSC-related CC, 
suggesting that there may be an association between low levels of Mucin-1 and PSC-related 
CC. In a cross-sectional study by Ince et al. published in 2014, they concluded that a 
combined assay of existing serum tumor markers may not be useful in differentiating benign 
from malignant strictures, due to the low specificity of the tumor markers which they had 
evaluated. Serum CEA was found to be elevated in patients with CC, with a sensitivity of 
68.6% and a specificity of 81.6%. Biliary CA 19-9 had the highest sensitivity of biliary tumor 
markers at 74%, but also the lowest specificity at 34.1%[16]. 
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Discussion of the Study Design and Methods 
Study Design. In this study bile from 37 patients was analyzed. Since the bile analyzed in this 
study was collected from patients who all had medical reasons for undergoing ERCP, an 
invasive intervention with strict indications, it was not possible to include a significant 
number of healthy controls. Instead, patients with benign biliary diseases (other than PSC) 
were assigned as controls. This may not be a weakness of the study since the patients who 
were included were a demographically good match for the patients in a future clinical setting 
where a tumor marker could be used for diagnosing biliary strictures of unknown etiology. To 
study patients free from biliary diseases might therefore not be relevant. In some cases the 
diagnosis was still uncertain before Nano LC-MS/MS analysis, since clinical investigations 
were either still in progress, or the patient had died and investigations had been inconclusive. 
Such patients were categorized as having CC or PSC when that respective disease was 
strongly suspected based on the results of several diagnostic measures. This is of course a 
potential source of error, as some patients included in the "CC and PSC" group may have had 
only one of these diseases. A final decision on how to categorize these difficult cases was 
reached after discussions with an experienced clinician. 
 
As this was an exploratory study 37 patients is quite a large number compared to earlier 
studies of the bile proteome. However, the hypothesis that there is a differential abundance of 
biliary proteins between patient groups could likely have been tested with more confidence if 
the sample size of patients with de novo CC and CC with concurrent PSC had been larger. It 
was unfortunately not possible to analyze more of such patients in this study, due to 
limitations of time and the number of patients with those respective diagnoses included in the 
larger study. Hopefully, the results of this study are valid enough that further studies, more 
targeted at the proteins described here and with larger study populations, can better elucidate 
the usefulness of these proteins as clinical biomarkers for CC. 
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As described previously, many differences exist in how the subtypes of CC behave 
clinically[1,2]. In this study, all cases of de novo CC were in practice treated as having the 
same disease, as were the "CC and PSC" cases, regardless of the subtype of cancer these 
patients had. The conclusions drawn from the results of the current study may therefore not be 
generalizable to all subtypes of CC, as most of the patients whose bile was analyzed had 
Klatskin type lesions. For future larger studies of the bile proteome it would be prudent, if 
possible, to include representatives of all subtypes of CC. Furthermore, a more equal gender 
distribution might also be advantageous for future studies. The current study did not attempt 
to examine if the gender of a patient is a factor that affects the composition of biliary proteins, 
and it would have been difficult to do so given the small sample sizes. 
 
Optimization of Methods. To evaluate the efficacy of the experimental method, Nano LC-
MS/MS analyses were performed continuously on the bile samples and the results were 
discussed. The first month of the study was spent optimizing the protocol for bile sample 
preparation and the gradient of the liquid chromatography mobile phase. Problems were 
encountered with obstruction of the column, as well as inadequate mass spectra, due to the 
large amount of proteins in the samples that we analyzed (Fig. 8). The sheer amount of 
sample also gave rise to long centrifugation times during ultrafiltration. After each Nano LC-
MS/MS analysis the raw data was converted to peak lists and searched with Mascot software 
against a database of human peptide sequences. These searches indicated how many proteins 
were identified in each bile sample; information that was useful when deciding how to 
optimize the method. 
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Figure 8. Mass spectrum for bile sample from a patient with CC, before the sample preparation method had been 
optimized. Note the wide and indistinct peaks. 
 
 
Figure 9. Mass spectrum for bile from the same patient as in Fig. 8, after the method had been optimized to 
decrease the protein concentration in the samples. The same mobile phase gradient was used in this analysis and 
the one shown in Fig. 8. 
 
Bile Sample Preparation. The chemical composition of bile poses certain difficulties when it 
comes to proteomic analysis, all of which need to be considered during sample preparation. 
The purpose of sample preparation of bile is to remove as much unwanted material as 
possible, mainly bile salts and lipids, while retaining the proteins for analysis. Proteins 
amount to only 7% of the total solute concentration of bile[17]. The first course of action 
during optimization of the sample preparation protocol was to lower the volume of bile 
loaded onto the ultrafiltration device, from an initial volume of 60 µl down to 6 µl (diluted in 
6 µl H2O). Even smaller bile volumes were evaluated, but these were difficult to work with 
and yielded too few protein identifications to be acceptable. Initially, ultrafiltration devices 
with a molecular weight cut-off of 10 kDa were used. Mainly hoping to shorten centrifugation 
times, ultrafiltration devices with a molecular weight cut-off of 30 kDa were evaluated. The 
30 kDa filters not only shortened centrifugation times, but also yielded a slight increase in the 
amount of peptide identifications when compared with samples prepared on filters with a 10 
kDa molecular weight cut-off. 30 kDa filters were thus chosen instead. 
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Bile contains large amounts of lipids that need to be removed, as they may interfere with the 
proteomic analysis[40]. The lipid removal reagent Cleanascite was used for delipidation. There 
was some concern whether the bile samples were being properly delipidated or not. The 
efficacy of lipid removal by Cleanascite has been shown to be in the range of 61 to 70% in 
one study conducted on human serum samples[41]. The ratio of Cleanascite to sample was 
increased from 1:4 to 1:3, to achieve a greater lipid removal. A protocol where the 
delipidation process was performed twice was also attempted. However, this double 
delipidation yielded few peptide identifications after analysis and was deemed unsatisfactory. 
 
Mucins are present in varying amounts in human bile. They are large glycoproteins that are 
difficult to denature, due to their abundant glycosylations[42]. In this study, some of the 
chemical reagents used in the original FASP protocol were substituted with others, e.g. the 
use of GuHCl instead of urea. GuHCl is a stronger protein denaturant than urea, with a 
general effectiveness of 2 to 2.5-fold that of urea[43]. This property is helpful for preparation 
of samples containing mucins, in order to ensure denaturation. 
 
Bile also contains bile salts, which were removed by desalting the samples on C18 StageTips. 
Advantages of this method is that the StageTips accommodate large volumes of sample to be 
loaded and desalted, while a low and concentrated volume of sample can be eluted[20]. 
 
The last major alteration to the sample preparation protocol was the change from digestion 
with only trypsin to double digestion with Lys-C and trypsin. This method has proven 
advantages over digestion where only trypsin is used, in terms of the number of peptide 
identifications by mass spectrometric measurements[44]. 
 
It was found that the protein concentration of the prepared samples exceeded the maximum 
capacity of the mass spectrometer, as manifested in the high electrical signal produced during 
Gustafsson A. 31 
ion detection. This high protein concentration was probably the culprit in the obstruction of 
the liquid chromatograph column. Consequently, the prepared samples of bile were diluted by 
a factor of 10 in 0.2% formic acid. Unfortunately, lowering the peptide concentration in the 
samples came at the cost of less peptide identifications, particularly of the low-abundance 
proteins. Because the most abundant proteins in bile number only a handful, while an 
overwhelming majority of biliary proteins are much less abundant, the high-abundance 
proteins prevent the identification of these less abundant proteins due to dynamic range 
issues[15]. In this study, albumin was the most abundant protein in the majority of bile 
samples, followed by hemoglobin, a blood contaminant. It is possible to use methods such as 
lectin affinity chromatography or immunoglobulin depletion to remove the high-abundance 
proteins from bile[15]. Some of the drawbacks of depletion, as summed up by Frantzi et al., are 
"issues concerning … reproducibility, [the] co-depletion of proteins of interest, [and the] 
requirement of higher amount of starting material"[45]. Due to time limitations the desalting 
process was not optimized in this study, but the samples would probably have been less 
concentrated if a smaller volume of sample had been loaded onto the StageTips. Decreasing 
this volume is almost certainly preferable over dilution of the final sample, since inaccuracies 
can be introduced during the dilution process if all samples are not treated equally. 
 
Changes to the Liquid Chromatography Mobile Phase Gradient. In the first method the 
chemical composition of the mobile phase was changed over time with a linear gradient. The 
gradient started with 10% mobile phase B, increasing to 30% at 90 min and reaching 100% at 
103 min. With a starting concentration of 10% mobile phase B, most of the peptides were 
eluted during the first 30 min of the method, yielding indistinct peaks in the mass spectra. 
Next, three different methods were evaluated, all of which had a lower starting concentration 
of mobile phase B, to allow a more gradual elution of peptides and a better separation of 
peaks. The second method was 103 min long and started with a 5% concentration of mobile 
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phase B, increasing slowly to 25% at 95 min and 100% at 103 min. The third method had a 
similar gradient steepness, but was only 60 min long. The fourth method (Table 2) was 108 
min long, with the gradient shaped in a stepwise fashion. The third and fourth methods were 
compared with each other by analyzing the same four bile samples with each method. The 
third method yielded an average of 320 protein identifications (range 140-402) and the fourth 
yielded an average of 341 protein identifications (range 148-447). The fourth method was 
used for the final large-scale Nano LC-MS/MS analysis of all 37 samples. 
 
Nano LC-MS/MS Analysis. Tandem mass spectrometry is often used for proteomic analysis. 
It is a fast method of fragmenting large amounts of peptides and determining their peptide 
sequences with high sensitivity and resolution[46]. It is advantageous to normalize the peptide 
intensities before LC-MS/MS analysis by spiking all samples with a defined quantity of a 
peptide with a known peptide sequence as an internal standard[45], to ensure that the protein 
contents are correctly quantified, and that no systematic differences in protein concentration 
are introduced during sample preparation. Since the samples were not normalized in this 
study, this is another potential error source. 
 
Data Analysis. The statistical analyses were performed with either of two non-parametric 
tests: the Mann-Whitney U-test for comparing two patient groups with each other, and the 
Kruskal-Wallis test for comparing more than two patient groups with each other. Non-
parametric tests were used because the sample sizes of the patient groups were quite small, 
ranging from 4-15 patients. Further, it was not assumed that the abundance of each tested 
protein was normally distributed between samples, rendering parametric tests unsuitable for 
this study. 
 
Multiple comparisons were tested during analysis, so the number of false positive results is 
expected to be higher than if only a single hypothesis had been tested. This can be corrected 
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by adjusting the significance level to a lower value, but in this study the significance level 
was not adjusted, since this is an exploratory study aimed at discovering a few potential 
biomarker candidates among over 900 identified biliary proteins. 
 
Principal component analysis was used to group the 910 proteins identified with MaxQuant 
according to their abundance. The analysis did not show clustering according to diagnosis for 
any of the components. This could be due to large differences between samples in the amount 
of protein identifications, or how much contamination with blood there was. 
 
Only a very limited number of proteins were selected for non-parametric analyses, and it is 
possible that the proteins described in the results section of this report are not the best 
biomarkers for CC, but they are a start. The list that can be found as Table 5 in the Appendix 
contains many additional interesting proteins, some of which might even be better biomarker 
candidates than the ones discussed earlier. It is clear that much remains to be studied in the 
search for biomarkers for CC. 
 
Conclusions 
For six of the proteins analyzed with non-parametric tests in this study, the relative abundance 
in human bile differed depending on the underlying disease of the patient (Table 3). R-PTP-
eta was able to differentiate patients with CC (including patients with concurrent PSC) from 
patients with PSC only, as well as from patients with other benign diseases of the bile ducts 
(Fig. 2AB). It is expressed by the PTPRJ gene, which is a known tumor suppressor[23]. Mucin-
1 was able to differentiate patients with de novo CC from patients with CC and concurrent 
PSC (Fig. 3), which hints at a different pathogenesis for CC depending on if it develops de 
novo or in a patient with PSC. The copper-binding protein Ceruloplasmin was able to 
differentiate CC from pancreatic cancer (Fig. 6B). None of the biliary proteins described in 
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this study were able to alone differentiate between a benign and malignant stricture in patients 
with PSC. The methods used in this study for preparation of bile samples yielded an 
acceptable amount of protein identifications, but tended to cause obstruction of the liquid 
chromatograph column. These methods should be optimized further, for example by 
evaluating the possibility of using even smaller volumes of bile during the desalting process. 
Further studies specifically targeted at the proteins described in this study, and with larger 
populations, are warranted to examine if these proteins have potential as clinically useful 
tumor markers for CC. Perhaps an immunoassay combining some of these proteins could 
provide an acceptable diagnostic accuracy for determining the etiology of bile duct strictures, 
even in patients with PSC. Such a fluid-based biomarker assay could be used both for 
detecting bile duct malignancies in symptomatic patients, and for screening high-risk 
populations, such as asymptomatic PSC patients. 
 
POPULÄRVETENSKAPLIG SAMMANFATTNING 
Gallvägscancer är en relativt ovanlig sjukdom, men är ändå den näst vanligaste typen av 
levercancer i Sverige: 237 personer insjuknade år 2013. Det är en mycket svårdiagnosticerad 
sjukdom med hög dödlighet, och i Sverige är den vanligaste riskfaktorn för sjukdomen just 
primär skleroserande kolangit. I den aktuella studien analyserades galla som samlats in på 
Sahlgrenska Universitetssjukhuset i Göteborgs Gastroenterologiska avdelning under perioden 
januari 2014 - januari 2015, från patienter som genomgick en röntgenundersökning som 
kallas ERCP, där en böjlig slang leds genom munnen och tarmen och slutligen in i 
gallvägarna, där en röntgenbild av gallvägarna tas efter injektion av kontrastmedel. 
Sammanlagt analyserades galla från 37 patienter. Patienterna som ingick i studien delades in i 
olika grupper beroende på vilken sjukdom de hade vid undersökningstillfället. Grupperna var: 
patienter med gallvägscancer med eller utan samtidig primär skleroserande kolangit, patienter 
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med cancer i bukspottskörteln, patienter med endast primär skleroserande kolangit, och 
patienter med andra godartade gallvägstillstånd, t.ex. gallsten. De olika proteinerna som fanns 
i gallan identifierades och deras mängd uppmättes med hjälp av en teknik som kallas 
vätskekromatografi med masspektrometri, varefter skillnaden i proteinhalter jämfördes mellan 
de olika sjukdomsgrupperna med statistiska analysmetoder. I dagsläget finns det inga 
laboratorieprover för att utesluta eller ställa diagnosen gallvägscancer. Resultaten från denna 
studien visar att det finns proteiner som möjligen kan fungera som tumörmarkörer i ett sådant 
laboratorieprov, men det krävs fortsatta studier på dessa proteiner innan ett sådant prov kan 
användas för rutinmässig diagnostik av gallvägscancer. 
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APPENDIX: TABLES 
 
 
 
Table 4. 
The amount of protein identifications for each patient. 
Diagnosis Protein identifications (n) 
CC 333 
CC (Klatskin tumor) 536 
CC (distal tumor) 571 
CC (Klatskin tumor) 653 
CC (Klatskin tumor) 299 
CC and PSC (Klatskin tumor) 202 
CC and PSC (Klatskin tumor) 487 
CC and PSC (Klatskin tumor) 672 
CC and PSC (intra-hepatic tumor) 416 
PSC 478 
PSC 723 
PSC 575 
PSC 613 
PSC 711 
PSC 238 
PSC 291 
Pancreatic cancer 296 
Pancreatic cancer 189 
Pancreatic cancer 197 
Pancreatic cancer 421 
Pancreatic cancer 172 
Pancreatic cancer 335 
Gallstones 389 
Gallstones 162 
Gallstones 423 
Gallstones 253 
Gallstones 265 
Gallstones 496 
Gallstones 346 
Gallstones 509 
Benign stricture (distal) 160 
Benign stricture (hilar) 666 
Benign stricture 611 
Benign stricture (distal) 155 
Cholecystitis 201 
Pancreatitis 423 
No current hepatobiliary disorder 142 
Abbreviations: CC, cholangiocarcinoma; PSC, primary sclerosing cholangitis. 
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Table 5. 
The 50 proteins that showed the greatest difference in relative abundance after t-tests. 
Majority protein name Gene name Present 
in (n) 
samples 
t-test performed on p-value 
Receptor-type tyrosine-protein 
phosphatase eta  
 
PTPRJ 17 all CC vs. controls; all CC vs. 
PSC, PAC, controls; de novo 
CC vs. controls. 
0.023; 0.007; 
0.026 
Thyroxine-binding globulin 
 
SERPINA7 28 all CC vs. controls. 0.033 
Ceruloplasmin 
 
CP 37 all CC vs. controls; all CC vs. 
PAC. 
0.038;  
0.032 
Vitamin D-binding protein 
 
GC 37 all CC vs. controls; all CC vs. 
PAC. 
0.0498;  
0.041 
Moesin 
 
MSN 17 all CC vs. PSC, PAC, controls. 0.025 
Tyrosine-protein phosphatase 
non-receptor type substrate 1 
SIRPA 35 all CC vs. PSC, PAC, controls. 0.036 
Porphobilinogen deaminase 
 
HMBS 6 all CC vs. PSC, PAC, controls. 0.039 
Cathelicidin antimicrobial 
peptide 
 
CAMP 23 all CC vs. PSC, PAC, controls; 
CC-PSC vs. PSC. 
0.041; 0.053 
Protein IGLV8-61 
 
IGLV8-61 17 all CC vs. PSC, PAC, controls. 0.047 
Mucin-5B MUC5B 36 de novo CC vs. CC-PSC. 0.052 
Annexin ANXA2 25 de novo CC vs. CC-PSC. 0.054 
Hypoxia up-regulated protein 1 
 
HYOU1 9 de novo CC vs. CC-PSC. 0.076 
 
Desmocollin-1 
 
DSC1 13 de novo CC vs. CC-PSC. 0.081 
 
Complement C5 C5 25 de novo CC vs. CC-PSC. 0.091 
 
Mucin-1 MUC1 22 de novo CC vs. CC-PSC. 0.106 
Osteopontin SPP1 29 CC-PSC vs. PSC 0.054 
Protein IGKV3D-20 IGKV3D-20 30 all CC vs. PAC; de novo CC vs. 
CC-PSC. 
0.014 
Ig heavy chain V-III region 
VH26 
IGHV3-23 25 all CC vs. PAC; de novo CC vs. 
PAC. 
0.017; 0.045 
 
Ig gamma-1 chain C region IGHG1 37 all CC vs. PAC. 0.021 
 
Protein IGHV4-34/59/61/39 IGHV4-34 36 all CC vs. PAC. 0.024 
 
Protein IGLV4-69 IGLV4-69 28 all CC vs. PAC. 0.025 
 
Hemoglobin subunit zeta HBZ 26 all CC vs. PAC. 0.027 
 
Ig lambda chain V-III region 
LOI 
- 37 all CC vs. PAC. 0.030 
 
Plastin-2 LCP1 30 all CC vs. PAC. 0.035 
 
Ig heavy chain V-I region EU - 37 all CC vs. PAC. 0.036 
 
Alpha-1B-glycoprotein A1BG 37 all CC vs. PAC. 0.038 
 
Profilin-1 PFN1 22 all CC vs. PAC. 0.038 
 
 
 
 
Gustafsson A. 41 
Table 5 (continued). 
The 50 proteins that showed the greatest difference in relative abundance after t-tests. 
Majority protein name Gene name Present 
in (n) 
samples 
t-test performed on p-value 
2-hydroxyacylsphingosine 1-
beta-galactosyltransferase 
UGT8 25 all CC vs. PAC. 0.040 
 
Ig heavy chain V-II region 
ARH-77 
- 27 all CC vs. PAC. 0.040 
 
Ig lambda chain V-I region 
NEWM 
- 29 all CC vs. PAC. 0.040 
 
Immunoglobulin lambda-like 
polypeptide 5 
IGLL5 37 all CC vs. PAC. 0.045 
 
Beta-2-microglobulin B2M 22 all CC vs. PAC. 0.043 
Ig lambda chain V-I region 
WAH 
- 32 all CC vs. PAC. 0.043 
 
Leucine-rich alpha-2-
glycoprotein 
LRG1 35 all CC vs. PAC. 0.044 
 
Ig kappa chain V-IV region IGKV4-1 34 all CC vs. PAC. 0.044 
 
Complement C3 C3 37 all CC vs. PAC. 0.045 
 
Vitronectin VTN 29 all CC vs. PAC. 0.048 
 
Serotransferrin TF 37 all CC vs. PAC. 0.048 
 
Ig gamma-3 chain C region IGHG3 27 all CC vs. PAC. 0.049 
 
UPF0556 protein C19orf10 C19orf10 18 de novo CC vs. PAC. 0.008 
78 kDa glucose-regulated 
protein 
HSPA5 28 de novo CC vs. PAC. 0.024 
Cathepsin S CTSS 21 de novo CC vs. PAC. 0.024 
Calreticulin CALR 35 de novo CC vs. PAC. 0.037 
Keratin, type II cytoskeletal 8 KRT8 34 de novo CC vs. PAC. 0.038 
Calmodulin CALM1;CA
LM2;CALM
3 
36 de novo CC vs. PAC. 0.042 
Heat shock 70 kDa protein 
1A/1B 
HSPA1A 21 de novo CC vs. PAC. 0.043 
Superoxide dismutase [Mn], 
mitochondrial 
SOD2 36 de novo CC vs. PAC. 0.044 
Triosephosphate isomerase TPI1 37 de novo CC vs. PAC. 0.044 
Cytosolic non-specific 
dipeptidase 
CNDP2 16 de novo CC vs. controls. 0.0001 
Ras-related C3 botulinum toxin 
substrate 1;2;3 
RAC1;RAC
2;RAC3 
10 de novo CC vs. controls. 0.049 
Abbreviations: all CC, all cases of cholangiocarcinoma including those with concurrent PSC; PSC, primary 
sclerosing cholangitis; PAC, pancreatic cancer; CC-PSC, cholangiocarcinoma with concurrent PSC. 
